Recent health news includes FDA's expanded approval of Sparsentan for kidney disease, positive results from Spyre's bowel drug trials, and a promising cancer treatment by Revolution Medicines.
Travere Therapeutics (TVTX) is back in focus after the U.S. FDA approved FILSPARI as the first and only therapy for focal segmental glomerulosclerosis in certain adults and children, thereby expanding ...
Recent advancements in health news highlight the FDA's approval of Travere's drug for a rare kidney disease, new AI tools for ...
Travere Therapeutics, Inc. is rated a Buy, secured full FDA approval for Filspari in FSGS, and driving a 37% stock surge.
Investor's Business Daily on MSN
Travere Therapeutics sees its composite rating rise to 97
Travere Therapeutics saw an improvement in its IBD SmartSelect Composite Rating Wednesday, from 94 to 97.
Filspari is now indicated for patients with focal segmental glomerulosclerosis without nephrotic syndrome to target significant proteinuria reduction.
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Travere Therapeutics’ sparsentan receives US FDA nod to treat focal segmental glomerulosclerosis; the first and only approved medicine for FSGS: San Diego Wednesday, April 15, 2 ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
With the path to blockbusterland now in sight, Travere Therapeutics is ready to hit the ground running after Monday’s ...
A once-daily oral tablet, sparsentan is fully approved to reduce proteinuria in patients ages 8 and older with FSGS who do ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results